Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutantsCHEN, Y.-R; FU, Y.-N; LIN, C.-H et al.Oncogene (Basingstoke). 2006, Vol 25, Num 8, pp 1205-1215, issn 0950-9232, 11 p.Article

Gefitinib-Induced Paronychia: Response to Autologous Platelet-Rich PlasmaKWON, Soon-Hyo; CHOI, Jae-Woo; HONG, Jong-Soo et al.Archives of dermatology (1960). 2012, Vol 148, Num 12, pp 1399-1402, issn 0003-987X, 4 p.Article

Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signalingLÖBKE, Christian; LAIBLE, Mark; RAPPL, Claudia et al.Proteomics (Weinheim. Print). 2008, Vol 8, Num 8, pp 1586-1594, issn 1615-9853, 9 p.Article

Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging : Mass Spectrometry - One of the pillars of ProteomicsMARKO-VARGA, György; FEHNIGER, Thomas E; REZELI, Melinda et al.Journal of proteomics (Print). 2011, Vol 74, Num 7, pp 982-992, issn 1874-3919, 11 p.Article

Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathwayLU, P.-H; KUO, T.-C; CHANG, K.-C et al.British journal of dermatology (1951). 2011, Vol 164, Num 1, pp 38-46, issn 0007-0963, 9 p.Article

Antitumor activity of gefitinib in Malignant rhabdoid tumor cells in vitro and in vivoKUWAHARA, Yasumichi; HOSOI, Hajime; OSONE, Shinya et al.Clinical cancer research. 2004, Vol 10, Num 17, pp 5940-5948, issn 1078-0432, 9 p.Article

United States Food and Drug Administration Drug approval summary: Gefitinib (ZD1839; Iressa) tabletsCOHEN, Martin H; WILLIAMS, Grant A; BAIRD, Amy et al.Clinical cancer research. 2004, Vol 10, Num 4, pp 1212-1218, issn 1078-0432, 7 p.Article

Efficacité du gefitinib (Iressa) pour le traitement d'un carcinome bronchioloalvéolaire inopérable = Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinomaBAYLE, S; DESCOURT, R; GOUVA, S et al.Revue des maladies respiratoires. 2004, Vol 21, Num 1, pp 153-157, issn 0761-8425, 5 p.Article

Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung : Possible significance of CRTC1-MAML2 oncogeneO'NEILL, Iain D.Lung cancer. 2009, Vol 64, Num 1, pp 129-130, issn 0169-5002, 2 p.Article

Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibitionYANO, Seiichi; KONDO, Kaoru; YAMAGUCHI, Motonori et al.Anticancer research. 2003, Vol 23, Num 5A, pp 3639-3650, issn 0250-7005, 12 p.Article

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cellsBIANCHI, Laura; BRUZZESE, Francesca; BINI, Luca et al.Proteomics (Weinheim. Print). 2011, Vol 11, Num 18, pp 3725-3742, issn 1615-9853, 18 p.Article

Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinibASAMI, Kazuhiro; KAWAHARA, Masaaki; ATAGI, Shinji et al.Lung cancer. 2011, Vol 73, Num 2, pp 211-216, issn 0169-5002, 6 p.Article

N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J miceKISHINO, Daizo; KIURA, Katsuyuki; TAKIGAWA, Nagio et al.Lung cancer. 2009, Vol 65, Num 3, pp 284-289, issn 0169-5002, 6 p.Article

Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patientROGGERO, Enrico; GIANCARLA, Busi; ANTONELLA, Palumbo et al.Journal of neuro-oncology. 2005, Vol 71, Num 3, pp 277-280, issn 0167-594X, 4 p.Article

A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutationsKIM, Dong-Wan; LEE, Se-Hoon; JONG SEOK LEE et al.Lung cancer. 2011, Vol 71, Num 1, pp 65-69, issn 0169-5002, 5 p.Article

Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancerWU, Jenn-Yu; YU, Chong-Jen; SHIH, Jin-Yuan et al.Lung cancer. 2010, Vol 67, Num 3, pp 348-354, issn 0169-5002, 7 p.Article

Les inhibiteurs d'EGFR dans le cancer bronchique non à petites cellules: plus qu'hier et moins que demain = EGFR inhibitors in non-small cell lung cancer: More than yesterday (but less than tomorrow)CORTOT, A. B.Revue de pneumologie clinique (Paris). 2010, Vol 66, Num 6, pp 367-374, issn 0761-8417, 8 p.Article

Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activityKANDA, Shigeru; NABA, Alexandra; MIYATA, Yasuyoshi et al.International journal of oncology. 2009, Vol 35, Num 6, pp 1305-1312, issn 1019-6439, 8 p.Article

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLCPALLIS, A. G; SYRIGOS, K. N.Lung cancer. 2013, Vol 80, Num 2, pp 120-130, issn 0169-5002, 11 p.Article

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II studyOH, In-Jae; BAN, Hee-Jung; KIM, Kyu-Sik et al.Lung cancer. 2012, Vol 77, Num 1, pp 121-127, issn 0169-5002, 7 p.Article

Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with GefitinibFEI MA; TONG SUN; DONGXIN LIN et al.Lung cancer. 2009, Vol 66, Num 1, pp 114-119, issn 0169-5002, 6 p.Article

Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinomaHIJIYA, Naoki; MIYAWAKI, Michiyo; MORIYAMA, Masatsugu et al.Human pathology. 2008, Vol 39, Num 3, pp 316-323, issn 0046-8177, 8 p.Article

Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ('Iressa', ZD1839)TANNO, Sachie; OHSAKI, Yoshinobu; NAKANISHI, Kyoko et al.Oncology reports. 2004, Vol 12, Num 5, pp 1053-1057, issn 1021-335X, 5 p.Article

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinibPENG HE; GANG LI.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 2, pp 341-348, issn 0344-5704, 8 p.Article

Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancerJUNG HAN KIM; HYEONG SU KIM; JOO YOUNG JUNG et al.Lung cancer. 2009, Vol 64, Num 1, pp 121-123, issn 0169-5002, 3 p.Article